162 related articles for article (PubMed ID: 33435173)
1. Comprehensive Gene Expression Analyses of Immunohistochemically Defined Subgroups of Muscle-Invasive Urinary Bladder Urothelial Carcinoma.
Kim B; Jang I; Kim K; Jung M; Lee C; Park JH; Kim YA; Moon KC
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435173
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
Jung M; Kim B; Moon KC
Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
[TBL] [Abstract][Full Text] [Related]
3. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
[TBL] [Abstract][Full Text] [Related]
4. Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia.
Edgecombe A; Nguyen BN; Djordjevic B; Belanger EC; Mai KT
Appl Immunohistochem Mol Morphol; 2012 May; 20(3):264-71. PubMed ID: 22498670
[TBL] [Abstract][Full Text] [Related]
5. Stratification of urinary bladder carcinoma based on immunohistochemical expression of CK5, CK14 and CK20.
Al-Sharaky DR; Abdelwahed M; Asaad N; Foda A; Abdou AG
J Immunoassay Immunochem; 2021 May; 42(3):236-251. PubMed ID: 33213275
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional Analysis of Immunohistochemically Defined Subgroups of Non-Muscle-Invasive Papillary High-Grade Upper Tract Urothelial Carcinoma.
Jung M; Lee JH; Kim B; Park JH; Moon KC
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30699951
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of
Ecke TH; Kiani A; Schlomm T; Friedersdorff F; Rabien A; Jung K; Kilic E; Boström P; Tervahartiala M; Taimen P; Gleichenhagen J; Johnen G; Brüning T; Koch S; Roggisch J; Wirtz RM
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050010
[TBL] [Abstract][Full Text] [Related]
8. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
[TBL] [Abstract][Full Text] [Related]
9. Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion.
Haghayeghi K; Lu S; Matoso A; Schiff SF; Mueller-Leonhard C; Amin A
Virchows Arch; 2021 Sep; 479(3):515-521. PubMed ID: 34218288
[TBL] [Abstract][Full Text] [Related]
10. CK5, CK5/6, and double-stains CK7/CK5 and p53/CK5 discriminate in situ vs invasive urothelial cancer in the prostate.
Fichtenbaum EJ; Marsh WL; Zynger DL
Am J Clin Pathol; 2012 Aug; 138(2):190-7. PubMed ID: 22904129
[TBL] [Abstract][Full Text] [Related]
11. Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.
Jangir H; Nambirajan A; Seth A; Sahoo RK; Dinda AK; Nayak B; Kaushal S
Ann Diagn Pathol; 2019 Dec; 43():151397. PubMed ID: 31494492
[TBL] [Abstract][Full Text] [Related]
12. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder.
Calvete J; Larrinaga G; Errarte P; Martín AM; Dotor A; Esquinas C; Nunes-Xavier CE; Pulido R; López JI; Angulo JC
Hum Pathol; 2019 Sep; 91():61-68. PubMed ID: 31279874
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis.
Hashmi AA; Hussain ZF; Irfan M; Edhi MM; Kanwal S; Faridi N; Khan A
BMC Res Notes; 2018 Mar; 11(1):207. PubMed ID: 29587848
[TBL] [Abstract][Full Text] [Related]
14. Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer.
Muilwijk T; Akand M; Van der Aa F; De Coninck V; Claessens M; Hente R; Eckstein M; Allory Y; Libbrecht L; Joniau S; Gevaert T
J Cell Mol Med; 2021 Aug; 25(16):7890-7900. PubMed ID: 34184816
[TBL] [Abstract][Full Text] [Related]
15. Molecular and immunohistochemical evaluation of BAP-1 antibody in bladder cancer and comparison with luminal-basal subtyping.
Gürbüz BÇ; Topal CS; Sobay R; Alkurt G; Zemheri IE
Pathol Res Pract; 2021 Jan; 217():153308. PubMed ID: 33341088
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.
Sikic D; Keck B; Wach S; Taubert H; Wullich B; Goebell PJ; Kahlmeyer A; Olbert P; Isfort P; Nimphius W; Hartmann A; Giedl J;
PLoS One; 2017; 12(6):e0179602. PubMed ID: 28632777
[TBL] [Abstract][Full Text] [Related]
17. Utility of D2-40, Cytokeratin 5/6, and High-Molecular-weight Cytokeratin (Clone 34βE12) in Distinguishing Intraductal Spread of Urothelial Carcinoma From Prostatic Stromal Invasion.
Iakymenko OA; Briski LM; Delma KS; Jorda M; Kryvenko ON
Am J Surg Pathol; 2022 Apr; 46(4):454-463. PubMed ID: 34560681
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer.
Kobayashi K; Matsumoto H; Matsuyama H; Fujii N; Inoue R; Yamamoto Y; Nagao K
Oncol Rep; 2016 Nov; 36(5):2852-2860. PubMed ID: 27599396
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Luminal and Basal Phenotypes in Bladder Cancer.
Guo CC; Bondaruk J; Yao H; Wang Z; Zhang L; Lee S; Lee JG; Cogdell D; Zhang M; Yang G; Dadhania V; Choi W; Wei P; Gao J; Theodorescu D; Logothetis C; Dinney C; Kimmel M; Weinstein JN; McConkey DJ; Czerniak B
Sci Rep; 2020 Jun; 10(1):9743. PubMed ID: 32546765
[TBL] [Abstract][Full Text] [Related]
20. Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer.
Wang CC; Tsai YC; Jeng YM
PLoS One; 2019; 14(8):e0221785. PubMed ID: 31469885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
